• About us
• Contact

Advertisement

Person › Details

Jochen Orlowski (MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; Nasdaq: MOR))

Orlowski, Jochen (MorphoSys 201512– Corp Communications + IR Relations before 4SC AG + Süd-Chemie)

 

	Organisation	MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; Nasdaq: MOR)
	Group	MorphoSys (Group)
	Former/major organisation	4SC AG (FSE: VSC)
	Group	4SC (Group)
	Product	Ylanthia® antibody technology
	Product 2	public relations / investor relations / marcom (services)

Record changed: 2020-06-26

Advertisement

More documents for Jochen Orlowski

• [1] MorphoSys AG. (3/7/19). "Press Release: MorphoSys Provides Updates on L-MIND and B-MIND Clinical Trials of MOR208 in Relapsed/Refractory DLBCL". Planegg....
• [2] MorphoSys AG. (1/31/19). "Press Release: MorphoSys Announces Settlement in Patent Lawsuit with Janssen and Genmab". Planegg....
• [3] MorphoSys AG. (4/9/18). "Press Release (Ad hoc): MorphoSys Announces Launch of American Depositary Shares (ADS) Offering in the United States"....
• [4] MorphoSys AG. (3/22/18). "Press Release (Ad hoc): MorphoSys Files Registration Statement in the United States for a Proposed American Depositary Shares (ADS) Offering". Planegg....
• [5] MorphoSys AG. (2/15/17). "Press Release: District Court Grants MorphoSys's Request to Add Second Patent in Lawsuit with Janssen Biotech and Genmab". Planegg....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2023. Made in Germany.